Preliminary results from the MATINS study show that treatment with FP-1305 (bexmarilimab) antibody targeting CLEVER-1 changes the tumor microenvironment from immunosuppressive to antitumoral by, for example, switching the macrophage polarization from M2 to M1 type; increasing the level of interferon gamma, circulating CD8+ T cells, and natural killer cells; and decreasing the level of regulatory T-cells. Here, IFNG is linked to neoplasm.